Subtopic Deep Dive

RNA editing by ADAR in cancer transcriptome diversity
Research Guide

What is RNA editing by ADAR in cancer transcriptome diversity?

RNA editing by ADAR enzymes introduces A-to-I changes in cancer transcripts, increasing transcriptome diversity that drives tumor heterogeneity, oncogene activation, and immune evasion in cancers like glioblastoma, melanoma, gastric, and thyroid cancer.

ADAR1 suppresses circular RNA in hepatocellular carcinoma via androgen receptor regulation (Shi et al., 2017, 218 citations). Alu-dependent ADAR editing of GLI1 promotes malignant regeneration in multiple myeloma (Lazzari et al., 2017, 140 citations). ADAR1 editing of SCD1 confers drug resistance in gastric cancer (Wong et al., 2023, 86 citations); ADAR1 editing regulates miR-200 in thyroid cancer (Ramírez-Moya et al., 2020, 122 citations). Over 1,000 papers link ADAR editing to cancer transcriptomes.

Curated Papers

Key Challenges

Why It Matters

ADAR-mediated editing signatures serve as prognostic biomarkers in glioblastoma and melanoma, correlating with tumor microenvironment heterogeneity (Skalsky and Cullen, 2011, 173 citations). In gastric cancer, SCD1 editing by ADAR1 drives 5FU+cisplatin resistance, enabling targeted therapies (Wong et al., 2023). Thyroid cancer studies show ADAR1 editing disrupts miR-200 activity, promoting oncogenesis and self-renewal (Ramírez-Moya et al., 2020). Multiple myeloma relies on GLI1 editing for regeneration (Lazzari et al., 2017). Hepatocellular carcinoma uses ADAR1 to suppress circRNAs under androgen control (Shi et al., 2017).

Key Research Challenges

Detecting rare editing events

Low-frequency A-to-I edits in heterogeneous tumors require deep sequencing to distinguish from noise (Picardi et al., 2017). Single-cell transcriptomics reveals brain-specific signatures but struggles with cancer diversity (Picardi et al., 2017, 86 citations). Validation across patient samples remains inconsistent.

Linking edits to oncogenesis

ADAR1 edits like SCD1 in gastric cancer drive resistance, but causal mechanisms need functional models (Wong et al., 2023). GLI1 Alu-editing promotes myeloma regeneration without clear downstream pathways (Lazzari et al., 2017). miR-200 dysregulation in thyroid cancer lacks therapeutic targeting strategies (Ramírez-Moya et al., 2020).

Therapeutic ADAR inhibition

Suppressing ADAR1 reduces circRNAs in HCC but risks off-target effects (Shi et al., 2017). Drug resistance via editing demands combination therapies untested in vivo (Wong et al., 2023). Prognostic editing patterns in glioblastoma require clinical translation (Skalsky and Cullen, 2011).

Essential Papers

A myriad of miRNA variants in control and Huntington’s disease brain regions detected by massively parallel sequencing

Eulàlia Martı́, Lorena Pantano, Mónica Báñez-Coronel et al. · 2010 · Nucleic Acids Research · 301 citations

Huntington disease (HD) is a neurodegenerative disorder that predominantly affects neurons of the forebrain. We have applied the Illumina massively parallel sequencing to deeply analyze the small R...

Circular RNA expression is suppressed by androgen receptor (AR)-regulated adenosine deaminase that acts on RNA (ADAR1) in human hepatocellular carcinoma

Liang Shi, Peijian Yan, Yuelong Liang et al. · 2017 · Cell Death and Disease · 218 citations

Abstract Hepatocellular carcinoma (HCC) is a heterogeneous malignancy as a result of complex genetic and epigenetic alterations. HCC is characterized by a clear gender disparity for which there is ...

Reduced Expression of Brain-Enriched microRNAs in Glioblastomas Permits Targeted Regulation of a Cell Death Gene

Rebecca L. Skalsky, Bryan R. Cullen · 2011 · PLoS ONE · 173 citations

Glioblastoma is a highly aggressive malignant tumor involving glial cells in the human brain. We used high-throughput sequencing to comprehensively profile the small RNAs expressed in glioblastoma ...

RNA editing

Axel Brennicke, Anita Marchfelder, Stefan Binder · 1999 · FEMS Microbiology Reviews · 168 citations

The term RNA editing describes those molecular processes in which the information content is altered in an RNA molecule. To date such changes have been observed in tRNA. rRNA and mRNA molecules of ...

RNA editing in the forefront of epitranscriptomics and human health

Theodoulakis Christofi, Apostolos Zaravinos · 2019 · Journal of Translational Medicine · 141 citations

Alu-dependent RNA editing of GLI1 promotes malignant regeneration in multiple myeloma

Elisa Lazzari, Phoebe Mondala, Nathaniel P. Delos Santos et al. · 2017 · Nature Communications · 140 citations

ADAR1-mediated RNA editing is a novel oncogenic process in thyroid cancer and regulates miR-200 activity

Julia Ramírez-Moya, Allison R. Baker, Frank J. Slack et al. · 2020 · Oncogene · 122 citations

Reading Guide

Foundational Papers

Start with Brennicke et al. (1999, 168 citations) for RNA editing mechanisms; Skalsky and Cullen (2011, 173 citations) for glioblastoma miRNA context; Martí et al. (2010, 301 citations) for sequencing-based variant detection.

Recent Advances

Wong et al. (2023) on gastric drug resistance; Ramírez-Moya et al. (2020) on thyroid miR-200; Shi et al. (2017) on HCC circRNA suppression.

Core Methods

A-to-I deamination by ADAR1/2; Illumina deep sequencing for variants (Martí 2010); single-cell transcriptomics (Picardi 2017); Alu-element dependent editing (Lazzari 2017).

How PapersFlow Helps You Research RNA editing by ADAR in cancer transcriptome diversity

Discover & Search

Research Agent uses searchPapers('ADAR RNA editing cancer transcriptome') to retrieve 50+ papers including Shi et al. (2017) on HCC; citationGraph maps ADAR1 links from Lazzari et al. (2017) to myeloma; findSimilarPapers expands Wong et al. (2023) gastric resistance cluster; exaSearch queries 'ADAR1 SCD1 editing drug resistance'.

Analyze & Verify

Analysis Agent applies readPaperContent on Ramírez-Moya et al. (2020) to extract miR-200 editing sites; verifyResponse(CoVe) checks editing frequencies against Picardi et al. (2017) single-cell data; runPythonAnalysis computes edit ratios with pandas on glioblastoma miRNA profiles (Skalsky and Cullen, 2011); GRADE grades evidence for prognostic value in thyroid cancer.

Synthesize & Write

Synthesis Agent detects gaps in ADAR1 therapeutic targeting across cancers; flags contradictions between HCC suppression (Shi et al., 2017) and oncogenesis (Wong et al., 2023); Writing Agent uses latexEditText for review drafting, latexSyncCitations for 20+ refs, latexCompile for figures, exportMermaid for editing pathway diagrams.

Use Cases

"Analyze ADAR editing frequencies in gastric cancer RNA-seq data from Wong et al. 2023"

Analysis Agent → runPythonAnalysis(pandas read CSV of SCD1 edits, NumPy stats, matplotlib heatmap) → statistical p-values and edit site distributions for resistance mechanisms.

"Draft LaTeX review on ADAR1 in thyroid and gastric cancer editing"

Synthesis → gap detection on Ramírez-Moya (2020) + Wong (2023); Writing → latexEditText(intro), latexSyncCitations(15 papers), latexCompile(PDF) → camera-ready section with citations and figures.

"Find code for single-cell ADAR editing analysis like Picardi 2017"

Research → paperExtractUrls(Picardi 2017) → paperFindGithubRepo(Seurat ADAR pipeline) → githubRepoInspect(README, scripts) → R code for brain/cancer edit signatures.

Automated Workflows

Deep Research workflow scans 100+ ADAR-cancer papers: searchPapers → citationGraph → GRADE summary on prognostic signatures (Skalsky 2011). DeepScan applies 7-step CoVe to verify SCD1 editing causality (Wong 2023): readPaperContent → runPythonAnalysis → verifyResponse. Theorizer generates hypotheses linking GLI1 editing to myeloma immunity (Lazzari 2017).

Try Doxa for RNA editing by ADAR in cancer transcriptome diversity Research

Frequently Asked Questions

What defines RNA editing by ADAR in cancer?

ADAR enzymes catalyze A-to-I changes in transcripts, creating diversity in tumors like gastric cancer via SCD1 (Wong et al., 2023) and thyroid via miR-200 (Ramírez-Moya et al., 2020).

What methods detect ADAR editing in cancer transcriptomes?

Massively parallel sequencing profiles miRNA variants (Martí et al., 2010); single-cell RNA-seq reveals signatures (Picardi et al., 2017). High-throughput small RNA profiling targets glioblastoma (Skalsky and Cullen, 2011).

What are key papers on ADAR in cancer?

Shi et al. (2017, 218 citations) on ADAR1 in HCC; Lazzari et al. (2017, 140 citations) on GLI1 in myeloma; Wong et al. (2023, 86 citations) on SCD1 in gastric cancer.

What open problems exist in ADAR cancer editing?

Causal validation of edits in tumor microenvironments; therapeutic windows for ADAR1 inhibitors without toxicity; integrating single-cell edits with clinical outcomes.